Clinical study with VagiVital® shows significant symptom relief in women undergoing cancer treatment and suffering from vaginal atrophy
Stockholm September 3, 2020 - Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs about the results of the latest clinical study with VagiVital®. The objective of this study was to investigate whether, and to what extent, VagiVital® can relieve symptoms associated with vaginal atrophy in women taking aromatase inhibitors (antiestrogens) as part of their cancer treatment.The results show strong relief of the most bothersome symptoms such as vaginal dryness, vaginal itching and pain during sexual intercourse (dyspareunia). In addition, vaginal pH decreased as a result of treatment